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What is the role of intra-aortic balloon counterpulsation in acute
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Percutaneous coronary intervention (PCI)
in  the  presence  of  impaired  left  ventricular
function is associated with significant mortal-
ity and morbidity, principally when the under-
lying coronary artery disease (CAD) subtends
a large proportion of viable myocardium.1 The
consequences  of  the  ischemic  cascade  are
particularly marked in this subset of patients,
whose diminished physiological reserve ren-
ders them less able to withstand the conse-
quences of ischemia or arrhythmias occurring
during a PCI procedure. This may result in a
deleterious downward spiral of hemodynamic
compromise,  culminating  in  cardiogenic
shock or death. Intra-aortic balloon counter-
pulsation  simultaneously  increases  coronary
blood flow, by augmentation of the diastolic
aorto-coronary  pressure  gradient,  and
decreases  myocardial  oxygen  demand,  by
reducing  the  end-diastolic  pressure,  and,
therefore,  the  after-load.  This  makes  it  an
attractive means of ameliorating ischemia and
consequently enhancing cardiac output. 
Contemporary  registry  evidence  suggests
that  cardiogenic  shock  and  high-risk  PCI
remain the commonest indications for intra-
aortic  balloon  pump  (IABP)  use,  with  the
American  College  of  Cardiology/American
Heart  Association  and  European  Society  of
Cardiology classifying the use of an IABP as a
1B  and  1C  recommendation,  respectively.2-4
However, at present, international guidelines
do not offer formal recommendations for the
use of IABP outside the setting of shock, but
recommend counterpulsation in patients at the
extreme end of the spectrum of hemodynamic
compromise. 
The use of IABP in the context of ST-eleva-
tion myocardial infarction (STEMI) has been
postulated  as  a  potential  clinical  scenario
where the added hemodynamic support afford-
ed  by  the  device  may  improve  outcomes,
reducing infarct size, and, therefore, reducing
morbidity and mortality, in both the short and
long term. However, previous randomized con-
trol data by Stone et al. in PAMI-II5 had shown
a lack of discernible benefit from routine use
of IABP, with major cardiovascular mortality
and morbidity end points and left ventricular
ejection fraction at 6-months in the IABP arm
being no different to those treated conserva-
tively. Furthermore, Sjauw et al.6 reported a
meta-analysis  of  the  1,009  patients  studied
across seven randomized trials of IABP use in
STEMI. However, an important caveat for all of
the trials included in this analysis was that
IABP therapy was instituted after initial pri-
mary PCI; therefore, the question regarding
whether  up-front IABP  therapy  may  provide
additive benefit to PPCI had not been defini-
tively  answered.  Contrary  to  these  previous
clinical trials, recent animal model data have
suggested increased myocardial salvage with
left  ventricular  unloading  provided  by  early
routine use of the IABP.7-9
The  Counterpulsation  to  Reduce  Infarct
Size  Pre-PCI  Acute  Myocardial  Infarction
(CRISP AMI) trial was a multi-center random-
ized control trial assessing the role of routine
use  of  IABP  in  patients  presenting  with
myocardial infarction, in the absence of car-
diogenic shock.10,11 Three hundred and thirty-
seven patients with anterior MI were random-
ized  to  mandated  placement  of  IABP  before
PCI, compared to standard of care (SOC) PCI,
without IABP support (161 to IABP+PCI and
176 to PCI alone). The primary end point was
infarct size, using well-validated late-gadolini-
um  enhancement  cardiac  MRI  (CMR)  tech-
niques,12,13 to determine the overall myocar-
dial infarction volume, as a proportion of the
entire left ventricular mass, performed at Days
3-5 of the index event. The enrolled population
had  clinical  features  consistent  with  large
anterior STEMIs (60% had more than 6 mm of
ST segment elevation on ECG and 63% had
culprit lesions in the proximal LAD) but were
hemodynamically stable at outset. The mean
infarct size in the SOC group was 37.5% of LV
mass, confirming that the study had sufficient
power  to  address  the  primary  hypothesis.
However, pre-procedure IABP insertion failed
to reduce infarct size; mean infarct size in the
IABP group was 42.1%, a difference of 4.6%
(95% CI, −0.2% to 9.4%], P=0.06. This finding
was  mirrored  in  the  pre-specified  subgroup
analysis  involving  only  those  patients  with
proximal LAD occlusion. The results suggest
that routine elective use of IABP in this set-
ting does not reduce infarct size. 
There are several reasons why the theoreti-
cally  protective  hemodynamic  effects  of  the
IABP device failed to show a clear difference
in the outcomes measured. Firstly, IABP inser-
tion itself may have delayed reperfusion time,
offsetting any potential gain from using the
device. Whilst Door-to-Balloon times were sig-
nificantly longer in the IABP group (77 min
IABP arm vs 68 min in PCI-only arm, P=0.04),
this did not translate into a significant differ-
ence in relation to pain-to-balloon time (203
vs 183  min,  respectively,  P=0.85),  which  is
considered a more important determinant of
infarct size. Therefore, any delay in reperfu-
sion was unlikely to be contributory. A more
plausible explanation for the lack of effect may
relate  to  the  duration  of  IABP  use  prior  to
revascularization, as this may have been too
short an interval to allow any hemodynamic
benefit to ameliorate coronary flow and unload
the left ventricle, and therefore aid myocardial
recovery.  Though  this  remains  a  possible
explanation,  given  that  time  is  muscle,  this
consideration is not applicable or relevant in
clinical practice. 
Mortality  at  six  months  was  numerically
lower in the group treated with IABP during
the index PPCI procedure but this difference
did  not  reach  statistical  significance,  likely
being  a  consequence  of  the  relatively  small
number of events [1.9% (n=3) IABP+PCI vs
5.2% (n=9) SOC, P=0.12]. Whilst these results
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do not support a strategy of routine insertion of
IABP in all patients undergoing PCI in the set-
ting of an anterior MI, without evidence of car-
diogenic  shock,  there  remains  an  important
caveat: one in 12 of those initially randomized
to  a  PCI-only  strategy  crossed-over  and
required bail out IABP therapy due to hemody-
namic deterioration prior to or following the
intended PCI. This cross-over population con-
sisted of 15 patients, 12 of whom had had sus-
tained  hypotension  or  developed  cardiogenic
shock. The MACE rate in this cross-over group,
requiring emergent IABP therapy, was dispro-
portionately increased. This is in keeping with
previous  findings,1,14 suggesting  that  whilst
bail-out IABP therapy is frequently life saving,
the need to acutely require increased hemody-
namic support indicates an adverse prognostic
marker.  The  importance  of  the  cross-over
cohort was borne out in the exploratory com-
posite end point of time to death, shock, or new
or worsening heart failure, which consisted of
8 events (5.0%) vs 21 events (12.0%) (P=0.03)
in the IABP+PCI compared to the PCI alone
arm, respectively. This was primarily driven by
the presence of an increased rate of cardio-
genic shock in the PCI alone group, compared
to the absence of cardiogenic shock events in
the IABP+PCI arm. Though not confirmatory,
there  is  an  important  indication  that  those
requiring  bail-out  may  be  patients  at  the
extreme  end  of  the  hemodynamic  spectrum,
Therefore,  whilst  bail-out  IABP  therapy
remains an important tool in the management
armoury, the ideal scenario would allow pre-
procedural prediction of the patient’s charac-
teristics  that  may  lead  to  potential  adverse
hemodynamic sequelae. However, the trial was
not sufficiently powered for subgroup analysis
and, therefore, could not attempt to generate a
model to predict this risk. 
Albeit addressing IABP use in distinct clini-
cal  scenarios,  there  are  several  interesting
similarities between the CRISP AMI findings
and those of the balloon-pump assisted coro-
nary intervention study (BCIS-1). BCIS-1 com-
pared the safety and efficacy of elective IABP
therapy during PCI with routine (unsupport-
ed) PCI in 301 patients with severe impair-
ment  of  left  ventricular  function  (mean  EF
23.6%) and extensive coronary disease (mean
jeopardy score 10.4; maximum possible score
12) who were hemodynamically stable at out-
set.15 Sixteen percent of those who underwent
unsupported PCI suffered major adverse car-
diac or cerebrovascular complications at hospi-
tal discharge, and it was not possible to reduce
the incidence of these complications by elec-
tive IABP insertion (15.2%). However, as with
the  recent  CRISP-AMI  findings,  a  trend  to
reduced 6-month mortality was noted in the
elective  IABP  arm.  Owing  to  the  relatively
small number of events at six months, it was
not possible to distinguish a treatment effect
related to IABP use from a statistical quirk, but
this question is likely to be addressed by the
BCIS-1  follow-up  study  which  is  currently
underway. Furthermore, 12% of those initially
randomized  to  receive  unsupported  PCI  suf-
fered  hemodynamic  compromise  during  the
procedure, sufficient to warrant rescue IABP
insertion  in  BCIS-1;  a  similar  proportion  to
those  needing  bail-out  IABP  in  CRISP-AMI.
Importantly, these patients were more likely to
suffer  periprocedural  infarction  than  those
who did not need IABP insertion, and required
a longer duration of IABP support than those
who received an IABP before PCI. As such, it is
important to acknowledge that a proportion of
patients  presenting  with  large  myocardial
infarctions and in high-risk stable CAD cases,
may  require  bail-out  IABP  insertion  during
PCI. Therefore a stand-by approach should be
adopted  when  undertaking  these  types  of
cases. The standby strategy itself is likely to
vary between centers; however, early priming
of the catheter laboratory staff for the potential
need  for  IABP  insertion  will  allow  timely
response if a balloon catheter is required.
In  contrast,  balloon  counterpulsation  is
often  considered  an  integral  therapy  when
managing cardiogenic shock, which continues
to be associated with mortality rates in excess
of 50%,16 despite advances in PCI techniques
and  management  algorithms  aimed  at  rapid
revascularization. However, to date, there are
no robust randomized trial data on IABP thera-
py in cardiogenic shock. Consequently, current
practice and recommendations are based upon
relatively  small  registries.  Sjauw  and  col-
leagues recently reported a meta-analysis of 9
such  registries,  including  over  10,000  shock
patients.6 This analysis showed an impressive
synergistic effect of IABP therapy and throm-
bolysis on survival, but interestingly no clear
benefit of IABP therapy was found in the pri-
mary PCI registries. Interpretation of this data
is hampered by the selection bias that is inher-
ent  in  registries,  as  exemplified  by  higher
revascularization  rates  in  patients  receiving
thrombolysis  as  well  as  IABP,  compared  to
those  who  were  treated  conservatively.
Notwithstanding  the  difficulties  of  studying
this group of patients, there is a clear need for
a randomized trial of IABP therapy in cardio-
genic shock and the on-going IABP SHOCK-2
trial17 seeks to fulfill this requirement, hoping
to  randomize  600  STEMI  patients  in  cardio-
genic  shock  to  receive  primary  PCI  with  or
without elective IABP support. 
Intra-aortic  balloon  pumps  remain  an
important adjunct to PCI in patients who have
an  increased  risk  of  death  or  major  cardiac
complications. The findings of CRISP-AMI and
BCIS-1 have clarified the role of elective IABP
during two different settings of high-risk PCI .
While these studies demonstrate that routine
IABP placement is not mandatory, a standby
approach  is  recommended,  as  an  important
minority may require bail-out IABP insertion
in  the  event  of  hemodynamic  compromise.
Ongoing RCTs are expected to strengthen the
evidence  base  relating  to  IABP  therapy,  but
there  is  considerable  heterogeneity  within
each of these groups, and translation of guide-
lines  to  individual  care  will  continue  to  be
based on estimation of risk and benefit in each
case.
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